DexCom, Inc. (NASDAQ:DXCM) Position Reduced by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. decreased its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 2.8% during the 4th quarter, Holdings Channel.com reports. The firm owned 443,001 shares of the medical device company’s stock after selling 12,694 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.’s holdings in DexCom were worth $34,452,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Congress Asset Management Co. raised its holdings in DexCom by 5,456.9% during the fourth quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company’s stock worth $105,529,000 after purchasing an additional 1,332,522 shares in the last quarter. Janney Montgomery Scott LLC raised its holdings in DexCom by 2,226.6% during the fourth quarter. Janney Montgomery Scott LLC now owns 232,543 shares of the medical device company’s stock worth $18,085,000 after purchasing an additional 222,548 shares in the last quarter. Proficio Capital Partners LLC bought a new stake in DexCom during the fourth quarter worth approximately $5,812,000. Mitsubishi UFJ Asset Management UK Ltd. raised its holdings in DexCom by 500.0% during the fourth quarter. Mitsubishi UFJ Asset Management UK Ltd. now owns 6,000 shares of the medical device company’s stock worth $467,000 after purchasing an additional 5,000 shares in the last quarter. Finally, Merit Financial Group LLC bought a new stake in DexCom during the fourth quarter worth approximately $228,000. Institutional investors own 97.75% of the company’s stock.

DexCom Trading Down 1.1%

NASDAQ DXCM opened at $84.11 on Wednesday. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $132.26. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The stock has a market cap of $32.98 billion, a price-to-earnings ratio of 58.82, a PEG ratio of 2.30 and a beta of 1.43. The firm’s 50 day moving average price is $71.23 and its two-hundred day moving average price is $77.35.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.01). DexCom had a return on equity of 30.14% and a net margin of 14.29%. The firm had revenue of $1.04 billion for the quarter, compared to analysts’ expectations of $1.02 billion. During the same quarter in the previous year, the firm posted $0.32 earnings per share. The company’s revenue for the quarter was up 12.5% on a year-over-year basis. Equities analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

Insider Activity

In other news, COO Jacob Steven Leach sold 14,076 shares of the business’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $990,668.88. Following the transaction, the chief operating officer now directly owns 313,497 shares in the company, valued at $22,063,918.86. The trade was a 4.30% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Jereme M. Sylvain sold 7,000 shares of DexCom stock in a transaction on Monday, March 10th. The shares were sold at an average price of $73.83, for a total transaction of $516,810.00. Following the completion of the sale, the executive vice president now directly owns 135,482 shares of the company’s stock, valued at approximately $10,002,636.06. The trade was a 4.91% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 66,926 shares of company stock worth $4,734,384 in the last ninety days. Corporate insiders own 0.32% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on DXCM shares. Cfra Research raised DexCom to a “hold” rating in a report on Friday, March 21st. Wells Fargo & Company reaffirmed an “overweight” rating on shares of DexCom in a report on Saturday, March 8th. Mizuho began coverage on DexCom in a report on Thursday, April 10th. They issued an “outperform” rating and a $85.00 price target on the stock. Redburn Atlantic raised DexCom from a “neutral” rating to a “buy” rating and upped their price target for the company from $85.00 to $115.00 in a report on Monday, February 3rd. Finally, Morgan Stanley upped their price target on DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a report on Friday, February 14th. Five equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, DexCom currently has a consensus rating of “Moderate Buy” and an average target price of $98.11.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.